SoftOx Solutions AS (OSL:SOFTX)

Market Cap	235.24M
Revenue (ttm)	9.31M
Net Income (ttm)	-19.65M
Shares Out	2.24B
EPS (ttm)	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,183,940
Average Volume	15,086,950
Open	0.0844
Previous Close	0.0844
Day's Range	0.0828 - 0.0880
52-Week Range	0.0100 - 0.2380
Beta	1.76
RSI	50.11
Earnings Date	Jun 10, 2025

About SoftOx Solutions AS

SoftOx Solutions AS, together with its subsidiaries, operates as a clinical-stage pharmaceutical company that develops antimicrobials products for infection prevention and treatment in Norway. The company develops SoftOx Inhalation Solution, an inhalation solution that is phase II clinical trial for the treatment of ventilator associated pneumonia and other airway infections. It is also developing antimicrobial pharmaceuticals targeting bacteria, viruses, and fungi. SoftOx Solutions AS was founded in 2012 and is headquartered in Fornebu, Norway...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 2
• Stock Exchange: Oslo Børs
• Ticker Symbol: SOFTX

Financial Performance

In 2024, SoftOx Solutions AS's revenue was 7.91 million, an increase of 13.38% compared to the previous year's 6.98 million. Losses were -42.94 million, 8.86% more than in 2023.